Genetic analysis of RET, GFRα1 and GDNF genes in Spanish families with multiple endocrine neoplasia type 2A

被引:31
作者
Gil, L
Azañedo, M
Pollán, M
Cristobal, E
Arribas, B
García-Albert, L
García-Sáiz, A
Maestro, ML
Torres, A
Menárguez, J
Rojas, JM
机构
[1] Ctr Nacl Biol Fundamental, Inst Salud Carlos III, Unidad Biol Celular, Madrid 28220, Spain
[2] Ctr Nacl Epidemiol, Inst Salud Carlos III, Madrid, Spain
[3] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[4] Ctr Nacl Microbiol Virol & Inmunol Sanitarias Maja, Inst Salud Carlos III, Madrid, Spain
[5] Hosp Univ San Carlos, Madrid, Spain
关键词
MEN; 2A; RET; GFR alpha 1; GDNF; polymorphisms; Spain;
D O I
10.1002/ijc.10298
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple endocrine neoplasia type 2A (MEN 2A) is associated with specific germline missense mutations in the RET proto-oncogene. This locus encodes a receptor tyrosine kinase whose activation requires the formation of a multimeric receptor complex including GDNF as a ligand and GFRalpha1 as a coreceptor. In order to explore the role of RET, GFRalpha1 and GDNF genes in the variation of phenotypes observed in MEN2A families, we analysed germline mutations of these genes in 4 unrelated Spanish MEN2A families (23 cases studied). We found 2 novel variants corresponding to a single change in position + 47 (intron 12) of RET and position +22 (intron 7) of GFRalpha1. Furthermore, we observed strong cosegregation between 2 polymorphisms of RET [G691S (exon 11) and S904S (TCC-TCG, exon IS) (100%, Fisher's exact test, p < 0.001)]. More interestingly, we found that these polymorphisms occurred at a significantly high frequency in patients with age at onset < 20 years old (Kruskal-Wallis's and Fisher's exact test, p = 0.007). These findings suggest that the G691S and S904S variants of RET may somehow play a role on the age of onset of MEN 2A. (C) 2002 Wilelv-Liss, Inc.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 44 条
[1]   Human GFRA1:: Cloning, mapping, genomic structure, and evaluation as a candidate gene for Hirschsprung disease susceptibility [J].
Angrist, M ;
Jing, SQ ;
Bolk, S ;
Bentley, K ;
Nallasamy, S ;
Halushka, M ;
Fox, GM ;
Chakravarti, A .
GENOMICS, 1998, 48 (03) :354-362
[2]   DIVERSITY OF RET PROTOONCOGENE MUTATIONS IN FAMILIAL AND SPORADIC HIRSCHSPRUNG DISEASE [J].
ATTIE, T ;
PELET, A ;
EDERY, P ;
ENG, C ;
MULLIGAN, LM ;
AMIEL, J ;
BOUTRAND, L ;
BELDJORD, C ;
NIHOULFEKETE, C ;
MUNNICH, A ;
PONDER, BAJ ;
LYONNET, S .
HUMAN MOLECULAR GENETICS, 1995, 4 (08) :1381-1386
[3]   TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret [J].
Baloh, RH ;
Tansey, MG ;
Golden, JP ;
Creedon, DJ ;
Heuckeroth, RO ;
Keck, CL ;
Zimonjic, DB ;
Popescu, NC ;
Johnson, EM ;
Milbrandt, J .
NEURON, 1997, 18 (05) :793-802
[4]   Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex [J].
Baloh, RH ;
Tansey, MG ;
Lampe, PA ;
Fahrner, TJ ;
Enomoto, H ;
Simburger, KS ;
Leitner, ML ;
Araki, T ;
Johnson, EM ;
Milbrandt, J .
NEURON, 1998, 21 (06) :1291-1302
[5]   Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression [J].
Borrego, S ;
Sáez, ME ;
Ruiz, A ;
Gimm, O ;
López-Alonso, M ;
Antiñolo, G ;
Eng, C .
JOURNAL OF MEDICAL GENETICS, 1999, 36 (10) :771-774
[6]   IDENTIFICATION OF A POLYMORPHISM IN EXON-11 OF THE RET PROTOONCOGENE [J].
BUGALHO, MJM ;
COTE, GJ ;
KHORANA, S ;
SCHULTZ, PN ;
GAGEL, RF .
HUMAN MOLECULAR GENETICS, 1994, 3 (12) :2263-2263
[7]   Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase [J].
BujBello, A ;
Adu, J ;
Pinon, LGP ;
Horton, A ;
Thompson, J ;
Rosenthal, A ;
Chinchetru, M ;
Buchman, VL ;
Davies, AM .
NATURE, 1997, 387 (6634) :721-724
[8]   Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease [J].
Carlomagno, F ;
Melillo, RM ;
Visconti, R ;
Salvatore, G ;
De Vita, G ;
Lupoli, G ;
Yu, YB ;
Jing, SQ ;
Vecchio, G ;
Fusco, A ;
Santoro, M .
ENDOCRINOLOGY, 1998, 139 (08) :3613-3619
[9]  
CECCHERINI I, 1994, ONCOGENE, V9, P3025
[10]  
Dahia PLM, 1997, CANCER RES, V57, P310